Biogen Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products address diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, Crohn's disease, and psoriasis.

Current Report (Form 8-K | Period ending 2024-10-28)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Biogen Inc (BIIB US)

Current Report (Form 8-K | Period ending 2024-10-28)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-10-30)

Current Report (Form 8-K | Period ending 2024-09-11)

Current Report (Form 8-K | Period ending 2024-08-12)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)